ImmuneOncia aims to develop immuno-oncology therapeutics

to transform the standard of care in cancer treatment

  • Technology
  • Platform

Platform

Focusing on the two key targets of immuno-oncology: T-cells and macrophages

Pipeline expansion leveraging the ImmuneOn-T/M Platform

Anti-PD-L1
Anti-LAG-3
Anti-Target A
Anti-Target B
Anti-CD47
Cytokine A
Toxin-Linker